Azitra, Inc. (AZTR)
| Market Cap | 3.67M |
| Revenue (ttm) | 97,500 |
| Net Income (ttm) | -9.03M |
| Shares Out | 7.63M |
| EPS (ttm) | -4.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 288 |
| Open | 0.481 |
| Previous Close | 0.498 |
| Day's Range | 0.471 - 0.507 |
| 52-Week Range | 0.426 - 68.400 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About AZTR
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR... [Read more]
Financial Performance
In 2023, Azitra's revenue was $686,000, an increase of 141.55% compared to the previous year's $284,000. Losses were -$12.64 million, -6.02% less than in 2022.
Financial StatementsNews
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates
BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra to Present at BIO-Europe 2024
BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #bioeurope2024--Azitra will present a corporate presentation at BIO-Europe 2024 in Stockholm on Monday, November 4.
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #Maxim--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress
BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #EADV2024--Azitra will be presenting a late-breaking presentation at #EADVCongress 2024 on Thursday, September 26.
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Compa...
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluatin...
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evalu...
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION ...
You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing
PALO ALTO, Calif.--(BUSINESS WIRE)--You.com, the AI-powered productivity engine, today announced a new strategic collaboration with Moesif, a leading provider of monetization and usage-based billing f...
Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities
TUSTIN, Calif.--(BUSINESS WIRE)--Wingspire Equipment Finance is proud to announce a $12,000,000 equipment financing to a leading aerospace manufacturing company. The Tier 1 aerospace manufacturer is k...
Azitra, Inc. Announces Pricing of $10.0 Million Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra, Inc. Announces Reverse Stock Split
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced p...
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced i...
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra, Inc. Announces Closing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, t...
Azitra, Inc. Announces Pricing of Public Offering
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...